Cascade Screening for Familial Hypercholesterolemia
Author Information
Author(s): Ned Renée M. Sijbrands, Eric J.G.
Primary Institution: Centers for Disease Control and Prevention
Hypothesis
The study aims to outline the available evidence on the clinical validity and utility of cascade screening for familial hypercholesterolemia (FH).
Conclusion
Cascade screening is an effective method for identifying individuals with familial hypercholesterolemia, which can lead to early diagnosis and treatment, reducing the risk of coronary heart disease.
Supporting Evidence
- Cascade screening has been shown to be a cost-effective method of identifying people with FH.
- Early detection and treatment with statins have been shown to reduce morbidity and mortality among those with heterozygous FH.
- Current DNA testing for FH is not 100% sensitive, as some mutations may not be assessed.
Takeaway
If someone in your family has a condition that makes their cholesterol very high, testing other family members can help find others who might have it too, so they can get treated early.
Methodology
The study reviews evidence on cascade screening, which involves testing biological relatives of diagnosed FH patients using LDL cholesterol measurements and genetic testing.
Potential Biases
There is a risk of false-negative and false-positive diagnoses, which can lead to inadequate or overtreatment.
Limitations
Fewer than 25% of individuals with FH are diagnosed, and many remain untreated or improperly treated.
Participant Demographics
The majority of affected individuals are heterozygotes, with a prevalence of 1 in 500 worldwide.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website